Related Experiment Video
Updated: Sep 13, 2025
08:12
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.6K
Association Between CD147 Expression, RAS Mutational Status, and Local Recurrence in Resected Locally Advanced Rectal
Anaëlle Isnard1,2, Laure-Amandine Cramier3, Rémi Vergara3
1CHU Bordeaux, Tumor Biology and Tumor Bank Laboratory, Pessac, France.
Cancer Medicine
|July 29, 2025
Summary
Tumor CD147 expression and mutational status were not linked to rectal cancer local recurrence. However, RAS mutations showed a link with CD147 expression in male patients, suggesting sex-related differences in tumor biology.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Local recurrence (LR) after rectal cancer (RC) treatment affects 5-10% of patients.
- Identifying high-risk patients for personalized management is crucial.
- Tumor pro-tumoral factors and genetic characteristics may influence LR potential.
Purpose of the Study:
- To evaluate the association of tumor CD147 expression and mutational status with post-resection RC LR.
- To investigate CD147 as a biomarker for cancer aggressiveness in RC.
Main Methods:
- Retrospective analysis of RC patients with and without LR post-chemoradiotherapy (CRT) and surgery.
- Immunohistochemistry for CD147 expression on residual tumors.
- Next-generation sequencing for mutational status assessment.
- Correlation analysis with LR rates.
Main Results:
- Pathological node invasion stage and number of invaded nodes were significantly associated with LR.
- CD147 expression and overall mutational status were not associated with LR.
- A notable association was found between RAS mutation and elevated CD147 expression, particularly in male patients (validated in an independent cohort).
Conclusions:
- CD147 tumor expression and mutational status are not directly associated with resected RC LR.
- The association between RAS mutation and CD147 expression in males supports the link between RAS mutations, tumor aggressiveness, and sex-related differences in colorectal cancer biology.
